Dermatology Licensing Deal Benchmarks 2026

IL-13 AD (Phase 2)

$2.4B

Atopic dermatitis

IL-17 Psoriasis (Phase 2)

$2.1B

Plaque psoriasis

JAK Inhibitor (Phase 2)

$1.7B

Alopecia areata

Derm Royalties

6.8%-13.5%

Base tier range

Model Your Deal

Market Analysis

Dermatology has become one of the fastest-growing therapeutic areas in biopharma licensing, driven by the success of biologics in immunodermatology. The dupilumab franchise ($13B+ annual revenue) validated the IL-4/IL-13 pathway, while IL-17 and IL-23 inhibitors have transformed psoriasis management. Phase 2 IL-13 inhibitor deals for atopic dermatitis carry a median total deal value of $2.4B, with IL-17 psoriasis deals at $2.1B.

Deal structures in dermatology reflect the large addressable populations (31M+ US AD patients, 7.5M psoriasis patients) and chronic treatment models that generate predictable recurring revenue. JAK inhibitor deals for emerging indications like alopecia areata and vitiligo average $1.7B, driven by the oral convenience advantage and broad inflammatory pathway coverage.

Royalty rates across dermatology licensing range from 6.8% to 13.5% at the base tier. Key deal drivers include efficacy superiority versus dupilumab, subcutaneous versus intravenous administration, dosing frequency advantages, and expansion potential across multiple inflammatory skin conditions. Topical biologics represent an emerging frontier with the potential to disrupt the systemics-dominated market.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are the highest-value dermatology deal modalities in 2026?

IL-13 and IL-4Ralpha inhibitors lead in deal value for atopic dermatitis ($2.4B at Phase 2), followed by IL-17 inhibitors for psoriasis ($2.1B). JAK inhibitors attract strong interest for emerging indications at $1.7B.

How do dermatology deal terms compare to oncology?

Dermatology deals tend to feature lower total deal values than oncology but offer more predictable commercial profiles due to large, well-defined patient populations and chronic treatment models. The recurring revenue model and lower clinical development risk (clear endpoints like EASI, PASI) make dermatology deals attractive on a risk-adjusted basis.

Which dermatology indications are most actively licensed?

Atopic dermatitis and plaque psoriasis lead in deal volume, followed by alopecia areata, vitiligo, hidradenitis suppurativa, and prurigo nodularis. The expansion of approved biologics into adjacencies (e.g., COPD, EoE for dupilumab) is driving increased interest in multi-indication licensing deals.

What trends are shaping dermatology licensing in 2026?

Key trends include the race for next-generation oral JAK inhibitors with improved safety profiles, topical biologic platforms targeting local inflammation, OX40/OX40L pathway inhibitors for AD, and biosimilar competition pressuring first-generation biologics. The growing focus on under-served conditions (hidradenitis, vitiligo) is creating new high-value deal opportunities.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Dermatology Licensing Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

IL-17 Inhibitor Deals

JAK Inhibitor Derm Deals

Phase 2 Deal Benchmarks

Small Molecule Deals

Ready to Calculate Your Deal Terms?